AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30157702 — intervention group
Group type: EXPERIMENTAL
Intervention: HPTN 052 clinical trial care and treatment
Number of subjects: 70
Study 30157702 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for joining the trial
Number of subjects: 70
Study 30157702 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to public HIV care centers
Number of subjects: 70
Study 30157702 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived clinical trial care
Number of subjects: 70
Study 30157702 — intervention group
Group type: EXPERIMENTAL
Intervention: Study benefits
Number of subjects: 70
Study 30157702 — intervention group
Group type: EXPERIMENTAL
Intervention: Public HIV care centers' attitude
Number of subjects: 70
Study 30157791 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 25
Study 30157791 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 25
Study 30157803 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated BEP chemotherapy
Number of subjects: 500
Study 30157803 — intervention group
Group type: COMPARATOR
Intervention: Standard BEP chemotherapy
Number of subjects: 500
Study 30157867 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Together (CT) intervention
Number of subjects: 20
Study 30157867 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Coping Together intervention
Number of subjects: 20
Study 30157920 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for three months
Number of subjects: 40
Study 30157920 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 30158155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 33
Study 30158223 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine programming attendance
Number of subjects: 0
Study 30158223 — intervention group
Group type: COMPARATOR
Intervention: Non-attendance of programming
Number of subjects: 0
Study 30158287 — intervention group
Group type: EXPERIMENTAL
Intervention: NETest
Number of subjects: 0
Study 30158288 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg per day for 56 days
Number of subjects: 19
Study 30158840 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy with HBOT for 10 sessions (combination therapy)
Number of subjects: 30
Study 30158840 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 30
Study 30158974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardial fat (PERI) measurement in women with PCOS
Number of subjects: 68
Study 30158974 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (no intervention specified)
Number of subjects: 68
Study 30159001 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (longitudinal estimate)
Number of subjects: 125
Study 30159001 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (cross-sectional prevalence)
Number of subjects: 125
Study 30159001 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of breastfeeding behaviors
Number of subjects: 125
Study 30159333 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently diagnosed type 2 diabetes
Number of subjects: 0
Study 30159333 — intervention group
Group type: COMPARATOR
Intervention: Recently diagnosed type 1 diabetes
Number of subjects: 0
Study 30159333 — intervention group
Group type: COMPARATOR
Intervention: Metabolically healthy individuals
Number of subjects: 0
Study 30160030 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 1922
Study 30160030 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 1922
Study 30160363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir, ombitasvir + dasabuvir (PTV/r/OBV/DSV) for 8 weeks
Number of subjects: 211
Study 30160585 — intervention group
Group type: EXPERIMENTAL
Intervention: Park use by women
Number of subjects: 0
Study 30160585 — intervention group
Group type: EXPERIMENTAL
Intervention: Park use by men
Number of subjects: 0
Study 30160585 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for seniors
Number of subjects: 0
Study 30160585 — intervention group
Group type: EXPERIMENTAL
Intervention: Park renovations
Number of subjects: 0
Study 30160804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 207
Study 30160804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachexia
Number of subjects: 207
Study 30160804 — intervention group
Group type: COMPARATOR
Intervention: No wasting
Number of subjects: 207
Study 30160804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia + Cachexia
Number of subjects: 207
Study 30160804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic HF
Number of subjects: 207
Study 30160804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachectic HF
Number of subjects: 207
Study 30161147 — intervention group
Group type: EXPERIMENTAL
Intervention: Option B PMTCT regimen (three-drug ART throughout pregnancy and breastfeeding, regardless of maternal CD4 count)
Number of subjects: 138
Study 30161147 — intervention group
Group type: EXPERIMENTAL
Intervention: Option B PMTCT regimen
Number of subjects: 138
Study 30165119 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress exposure phase with visual stimuli (Besancon Affective Picture Set-Adolescents)
Number of subjects: 81
Study 30165119 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort-seeking phase with visual stimuli
Number of subjects: 81
Study 30165119 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiological parameters
Number of subjects: 81
Study 30165185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative superior hypogastric plexus (SHP) block (Hypo; n=30)
Number of subjects: 60
Study 30165185 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative SHP block (No-Hypo; n=30)
Number of subjects: 60
Study 30165185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 30165500 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable consumption
Number of subjects: 400
Study 30165500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 400
Study 30165500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit consumption in RTRs with eGFR > 45 mL/min/1.73 m2
Number of subjects: 400
Study 30165500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit consumption in RTRs without proteinuria
Number of subjects: 400
Study 30165521 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3™ (HM3) LVAD
Number of subjects: 463
Study 30165570 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR estimated from serum creatinine
Number of subjects: 447
Study 30165570 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR estimated from serum cystatin C
Number of subjects: 447
Study 30165570 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR estimated from both serum creatinine and cystatin C
Number of subjects: 447
Study 30165570 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary albumin-to-creatinine ratio (ACR)
Number of subjects: 447
Study 30165599 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (high-MUFA) diet
Number of subjects: 980
Study 30165599 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (high-CHO) diet
Number of subjects: 980
Study 30165651 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of live herpes zoster vaccine (ZVL)
Number of subjects: 2
Study 30165651 — intervention group
Group type: COMPARATOR
Intervention: De novo immunization
Number of subjects: 2
Study 30165822 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for hospital staff
Number of subjects: 0
Study 30165894 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted internal limiting membrane insertion plus air tamponade
Number of subjects: 38
Study 30165894 — intervention group
Group type: COMPARATOR
Intervention: Conventional vitrectomy plus internal limiting membrane peeling plus silicone oil tamponade
Number of subjects: 38
Study 30166073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily) plus aspirin (75-100 mg daily) for 1 month, followed by ticagrelor monotherapy for 23 months
Number of subjects: 15968
Study 30166073 — intervention group
Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (75-100 mg aspirin daily plus either 75 mg clopidogrel daily or 90 mg ticagrelor twice daily for 12 months), followed by aspirin monotherapy for 12 months
Number of subjects: 15968
Study 30166253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r plus RIB) for 12 weeks
Number of subjects: 110
Study 30166274 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month physical activity program with activity tracker (Nokia Go)
Number of subjects: 60
Study 30166291 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) syndrome-targeted therapies
Number of subjects: 2000
Study 30166291 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) four diagnostic methods
Number of subjects: 2000
Study 30166293 — intervention group
Group type: EXPERIMENTAL
Intervention: TRANSIMMUNOM observational clinical protocol
Number of subjects: 25
Study 30166293 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems biology approaches
Number of subjects: 25
Study 30166295 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CABG 24 hours urinary TXA-M
Number of subjects: 1670
Study 30166295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate tertile of post-CABG 24 hours urinary TXA-M
Number of subjects: 1670
Study 30166295 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile of post-CABG 24 hours urinary TXA-M
Number of subjects: 1670
Study 30167089 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib (300 mg, n=6) plus paclitaxel (80 mg/m2)
Number of subjects: 19
Study 30167089 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib (250 mg, n=4) plus paclitaxel (80 mg/m2)
Number of subjects: 19
Study 30167089 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib (150 mg, n=9) plus paclitaxel (80 mg/m2)
Number of subjects: 19
Study 30167310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg two times a day
Number of subjects: 347
Study 30167310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 30167329 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 460
Study 30167329 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 460
Study 30167756 — intervention group
Group type: COMPARATOR
Intervention: OAT4
Number of subjects: 60
Study 30167756 — intervention group
Group type: COMPARATOR
Intervention: OCT2
Number of subjects: 60
Study 30167756 — intervention group
Group type: COMPARATOR
Intervention: OCT3
Number of subjects: 60
Study 30167756 — intervention group
Group type: COMPARATOR
Intervention: PEPT2
Number of subjects: 60
Study 30167756 — intervention group
Group type: EXPERIMENTAL
Intervention: OAT4-transfected cells
Number of subjects: 60
Study 30167756 — intervention group
Group type: EXPERIMENTAL
Intervention: PEPT2-transfected cells
Number of subjects: 60
Study 30167756 — intervention group
Group type: COMPARATOR
Intervention: OAT4 and PEPT2 genotypes
Number of subjects: 60
Study 30167809 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) for detection of AF
Number of subjects: 173
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: In-centre nocturnal hemodialysis (INHD, 7-8 h/session, 3×/week)
Number of subjects: 67
Study 30168083 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (CHD, 4 h/session, 3×/week)
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (INHD and CHD)
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LA and LV end-diastolic volume index (EDVi)
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LA and LV end-systolic volume index (ESVi)
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LA EF and LVEF
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LA and RV EDVi
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LA and RV ESVi
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LA ESVi and LV mass index
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexed LA volumes at baseline
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: LA EF at baseline
Number of subjects: 67
Study 30168083 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in biomarker levels after 52 weeks
Number of subjects: 67
Study 30168134 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks)
Number of subjects: 60
Study 30168134 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 60
Study 30168233 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra TPS implantation
Number of subjects: 720
Study 30168356 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) in addition to physiotherapy
Number of subjects: 23
Study 30168356 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT) only
Number of subjects: 23
Study 30168744 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment Tool
Number of subjects: 0
Study 30169182 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-hAADC gene therapy (bilateral intraputaminal injections, dosage not specified)
Number of subjects: 10
Study 30169223 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily
Number of subjects: 23
Study 30169354 — intervention group
Group type: EXPERIMENTAL
Intervention: BrainPort Vision Pro
Number of subjects: 17
Study 30169606 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical allocation of interventions focusing on hotspots of HIV transmission
Number of subjects: 714
Study 30169606 — intervention group
Group type: EXPERIMENTAL
Intervention: Geospatial analyses
Number of subjects: 714
Study 30169606 — intervention group
Group type: EXPERIMENTAL
Intervention: Slatkin-Maddison analyses
Number of subjects: 714
Study 30169669 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and neonatal vitamin D status (25(OH)D concentrations)
Number of subjects: 734
Study 30169669 — intervention group
Group type: EXPERIMENTAL
Intervention: Low antenatal vitamin D status (<30 nmol/L and <50 nmol/L)
Number of subjects: 734
Study 30169669 — intervention group
Group type: COMPARATOR
Intervention: Maternal 25(OH)D (per 10 nmol/L)
Number of subjects: 734
Study 30169669 — intervention group
Group type: COMPARATOR
Intervention: Cord 25(OH)D (per 10 nmol/L)
Number of subjects: 734
Study 30169719 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritative feeding style
Number of subjects: 0
Study 30169719 — intervention group
Group type: COMPARATOR
Intervention: Authoritarian feeding style
Number of subjects: 0
Study 30169752 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC hs-cTnT 0/1h-algorithm in young patients
Number of subjects: 2767
Study 30169752 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC hs-cTnT 0/1h-algorithm in middle-age patients
Number of subjects: 2767
Study 30169752 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC hs-cTnT 0/1h-algorithm in old patients
Number of subjects: 2767
Study 30169752 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative higher cut-off concentrations for older patients
Number of subjects: 2767
Study 30170075 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 200
Study 30170075 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 200
Study 30170561 — intervention group
Group type: EXPERIMENTAL
Intervention: Heckman's model for MNAR outcomes
Number of subjects: 500
Study 30170561 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed imputation approach
Number of subjects: 500
Study 30170561 — intervention group
Group type: COMPARATOR
Intervention: Complete case approach
Number of subjects: 500
Study 30170561 — intervention group
Group type: COMPARATOR
Intervention: Classical Heckman's model estimates
Number of subjects: 500
Study 30170575 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care provision, quality of life and death, elements of advance care planning, family caregivers' needs and satisfaction
Number of subjects: 200
Study 30170575 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-consensus recommendations derived from the study results
Number of subjects: 200
Study 30170575 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication of recommendations nationally and internationally
Number of subjects: 200
Study 30170630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) and low-dose ipilimumab (1 mg/kg)
Number of subjects: 1
Study 30170630 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric immune suppressive therapy (high dose steroids, tacrolimus, therapeutic plasma exchange)
Number of subjects: 1
Study 30170807 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 2017 stage C
Number of subjects: 959
Study 30170807 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 2017 stage D
Number of subjects: 959
Study 30170997 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of preoperative self-reported mechanical knee symptoms
Number of subjects: 641
Study 30171081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab 900 mg every 4 weeks (lower trough exposure)
Number of subjects: 39
Study 30171081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab 1800 mg every 4 weeks (higher trough exposure)
Number of subjects: 39
Study 30171081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab 1000 mg every 4 weeks, 1600 mg every 6 weeks, 2400 mg every 8 weeks, or 5400 mg every 12 weeks (study 201)
Number of subjects: 39
Study 30171081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (all cohorts)
Number of subjects: 39
Study 30171081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (higher-trough-exposure cohort)
Number of subjects: 39
Study 30171081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (lower-trough-exposure cohorts)
Number of subjects: 39
Study 30171354 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine-based equations for estimating GFR
Number of subjects: 96
Study 30171354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C-based equations for estimating GFR
Number of subjects: 96
Study 30171354 — intervention group
Group type: COMPARATOR
Intervention: Measured GFR (mGFR) by iohexol clearance
Number of subjects: 96
Study 30171779 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily on Days 3-32 and simvastatin 40 mg single doses on Days 1 and 31
Number of subjects: 52
Study 30171779 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily on Days 4-34 and rosuvastatin 20 mg single doses on Days 1 and 32
Number of subjects: 52
Study 30171797 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella vaccine (MMR)
Number of subjects: 44
Study 30172032 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory leukocyte protease inhibitor (SLPI)
Number of subjects: 556
Study 30172032 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor IL-6
Number of subjects: 556
Study 30172032 — intervention group
Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 556
Study 30172345 — intervention group
Group type: EXPERIMENTAL
Intervention: R2-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone + 25 mg oral Lenalidomide per day on days 1-14 for 6 cycles every 3 weeks)
Number of subjects: 80
Study 30172345 — intervention group
Group type: EXPERIMENTAL
Intervention: R2-CHOP
Number of subjects: 80
Study 30172739 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated antipsychotic dopamine receptor occupancy
Number of subjects: 0
Study 30172739 — intervention group
Group type: EXPERIMENTAL
Intervention: Premorbid IQ and cognition
Number of subjects: 0
Study 30173210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) injections
Number of subjects: 4
Study 30174209 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 9610
Study 30174209 — intervention group
Group type: EXPERIMENTAL
Intervention: TST-15
Number of subjects: 9610
Study 30174209 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold In-Tube
Number of subjects: 9610
Study 30174209 — intervention group
Group type: COMPARATOR
Intervention: TST-10
Number of subjects: 9610
Study 30174209 — intervention group
Group type: COMPARATOR
Intervention: TST-5
Number of subjects: 9610
Study 30174861 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA based EGFR mutation test
Number of subjects: 1001
Study 30174890 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ALI
Number of subjects: 130
Study 30174890 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 130
Study 30174890 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 130
Study 30174890 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Diastolic Blood Pressure (DBP)
Number of subjects: 130
Study 30174890 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 130
Study 30174890 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin I2/TXB2 ratio
Number of subjects: 130
Study 30174920 — intervention group
Group type: EXPERIMENTAL
Intervention: PACK Adult clinical decision support tool with educational outreach training for doctors and nurses
Number of subjects: 48
Study 30174920 — intervention group
Group type: COMPARATOR
Intervention: PACK Adult clinical decision support tool
Number of subjects: 48
Study 30174951 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg and pregabalin 150mg 1 hour before the operation
Number of subjects: 30